^
BIOMARKER:

BIRC3 mutation

i
Other names: BIRC3, API2, c-IAP2, cIAP2, hiap-1, MALT2, MIHC, RNF49, Baculoviral IAP repeat containing 3
Entrez ID:
Related biomarkers:
1m
Conclusion These results suggest that the multiregional sequencing of the different anatomical compartments of SLL is essential to gain a comprehensive view of the disease mutational landscape.  Consistently, mutational analysis of the SLL lymph node biopsy should be coupled to analysis of the circulating PB CD19+ cell compartment, and eventually with ctDNA analysis. This observation may have clinical relevance when treatment tailoring is based on specific gene mutations used as molecular predictors that might be present in only one specific anatomical compartment of the disease.
Circulating tumor DNA
|
NOTCH1 (Notch 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • CD19 (CD19 Molecule) • BIRC3 (Baculoviral IAP repeat containing 3) • CD5 (CD5 Molecule)
|
ASXL1 mutation • BIRC3 mutation
1m
Conclusion Based on these results, we conclude that SF3B1, EGR2, XPO1 and BIRC3 mutations independently predicted short TTFT and should be considered for extended molecular testing in CLL. However, considering the different impact of gene mutations in M-CLL and U-CLL, the IGHV mutation status must be taken into account when constructing future prognostic models including recurrent gene mutations.
Retrospective data • IO biomarker
|
TP53 (Tumor protein P53) • NOTCH1 (Notch 1) • SF3B1 (Splicing Factor 3b Subunit 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • IGH (Immunoglobulin Heavy Locus) • BIRC3 (Baculoviral IAP repeat containing 3) • XPO1 (Exportin 1) • POT1 (Protection of telomeres 1) • NFKBIE (NFKB Inhibitor Epsilon)
|
TP53 mutation • Chr del(11q) • SF3B1 mutation • BIRC3 mutation • IGH mutation • POT1 mutation • TS 12 • XPO1 mutation
4ms
Treatment of patients with CLL harbouring TP53-deficiency requires drugs that promote cell death independently of TP53. Novel and smarter therapies revolutionize the treatment of del(17p) and/or aberrant TP53 CLL, but development of alternative therapeutic approaches still remains an issue of critical importance.
Clinical • Review • Journal • IO biomarker
|
TP53 (Tumor protein P53) • NOTCH1 (Notch 1) • SF3B1 (Splicing Factor 3b Subunit 1) • BIRC3 (Baculoviral IAP repeat containing 3)
|
TP53 mutation • BIRC3 mutation • TP53 expression
7ms
Taken together, our results suggest that del(11q) CLL patients harboring BIRC3 mutations should be considered as a CLL subgroup at a high risk of progression that might benefit from venetoclax-based therapies. Funding: PI18/01500
IO biomarker
|
BCL2L1 (BCL2-like 1) • BIRC3 (Baculoviral IAP repeat containing 3) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
|
Chr del(11q) • BCL2 overexpression • BIRC3 mutation • BIRC3 deletion
|
Venclexta (venetoclax)
7ms
Methods In RESONATE-2 (NCT01722487), pts aged ≥65 years without del(17p) were randomized to single-agent ibr or chlorambucil (clb). Conclusions This integrated analysis of pts undergoing first-line ibr-based treatment, with up to 79 mo follow up, demonstrated similar PFS and ORR for ibr-treated pts with or without high-risk genomic features, and confirmed significant PFS and ORR benefits with ibr-based therapy versus clb (± obinutuzumab). This analysis across two phase 3 studies demonstrated the efficacy of first-line ibr-based treatment irrespective of cytogenetic and mutational risk features, including those with unmutated IGHV, NOTCH1 mutation, and those with the highest risk classification of del(17p)/TP53 mutation/BIRC3 mutation.
Clinical • P3 data • IO biomarker
|
TP53 (Tumor protein P53) • NOTCH1 (Notch 1) • SF3B1 (Splicing Factor 3b Subunit 1) • BIRC3 (Baculoviral IAP repeat containing 3)
|
TP53 mutation • Chr del(11q) • NOTCH1 mutation • TP53 mutation + Chr del(17p) • SF3B1 mutation • BIRC3 mutation
|
ibrutinib • Gazyva (obinutuzumab) • Leukeran (chlorambucil)
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our